AVDL (Avadel Pharmaceuticals PLC) Gross Margin

AVDL (Avadel Corp) - company brandmark

Steady demand for innovation makes Avadel Pharmaceuticals (AVDL) a defensive asset independent of macroeconomic trends. Gross profit margins visualize this growth, with the indicator currently standing at 94.50. The business relies on the expansion of Lumryz within the sleep disorders segment. High profitability with a small workforce is driven by a unique slow-release formula of the active substance.

AVDL - Avadel Pharma Gross Margin over the range 07/04/2022 - 02/28/2026

Comprehensive metric breakdowns and analytics for Avadel Pharmaceuticals (AVDL)

- share price and consensus valuation forecast:
Basic company analysis:Avadel Pharmaceuticals plc AVDL
Finished products of Avadel Corp

Gross margin measures production efficiency by determining the portion of revenue remaining after direct product costs, allowing investors to assess the business's intrinsic profitability. The trend in gross profit margins confirms the high value of the patented narcolepsy drug, which provides Avadel Pharmaceuticals (AVDL) with a long-term competitive advantage due to its unique formula and the scarcity of the niche in the US.